Abstract. Human mutagenesis is largely random, thus large coding regions, simply on the basis of probability, represent relatively large mutagenesis targets. Thus, we considered the possibility that large cytoskeletal-protein related coding regions (CPCRs), including extra-cellular matrix (ECM) coding regions, would have systemic nucleotide variants that are not present in common SNP databases. Presumably, such variants arose recently in development or in recent, preceding generations. Using matched breast cancer and blood-derived normal datasets from the cancer genome atlas, CPCR single nucleotide variants (SNVs) not present in the All SNPs(142) or 1000 Genomes databases were identified. Using the Protein Variation Effect Analyzer internet-based tool, it was discovered that apparent, systemic mutations (not shared among others in the analysis group) in the CPCRs, represented numerous deleterious amino acid substitutions. However, no such deleterious variants were identified among the (cancer blood-matched) variants shared by other members of the analysis group. These data indicate that private SNVs, which potentially have a medical consequence, occur de novo with significant frequency in the larger, human coding regions that collectively impact the cytoskeleton and ECM.
Introduction
Genetic damage is largely random and therefore tends to affect the larger, functional regions of the human genome more frequently than the smaller regions (1) . For example, a systematic study has revealed that cancer fusion genes, on average, are statistically, significantly larger than other human genes (2, 3) . The large introns of potential cancer fusion genes presumably allow for many different productive recombination opportunities, i.e., many recombinations that would allow for exon juxtaposition and the generation of hybrid proteins. Smaller cancer fusion genes tend to be associated with the rare types of cancer, for example EWS RNA binding protein 1 in Ewing's sarcoma.
Cytoskeleton-related protein coding regions (CPCRs), including extracellular matrix (ECM) proteins, are among the largest coding regions in the human genome and are heavily mutated in various types of cancer (1, 4, 5) . The possibility that these coding regions would also be commonly vulnerable to de novo mutations, or mutations occurring in relatively recent past-generations, was considered, and therefore had not been included in the conventional single nucleotide polymorphism (SNP) databases. In the present study, CPCR single nucleotide variants (SNVs) that appeared in The Cancer Genome Atlas (TCGA) normal blood and breast cancer (BRCA) sample datasets were identified. 'Non-unique' SNVs were discovered to be relatively common among a sample of 31 individuals, and SNVs specifically present in single individuals (i.e., private variations) were also common.
Materials and methods
Basic algorithm. The basic approach is indicated in Fig. 1 and the detailed steps are provided in the supporting online material (SOM) file, 'Stoll 2016 SOM Figure 1 , detailed protocol'; all of the SOM files are hosted at http://www.universityseminarassociates.com/Supporting_online_material_for_scholarly_pubs. php). Whole exome sequence (WXS) sample manifest files were downloaded from the Cancer Genomics Hub Browser (browser.cghub.ucsc.edu; approved NIH dbGaP project number 6300) using the following filters: 'Breast invasive carcinoma' under 'By Disease'; 'Blood Derived Normal' and 'Primary Solid Tumor' under 'By Sample Type'; 'WXS' under 'By Library Type'; and 'GRCH37/HG19' under 'By Assembly'.
De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions Search results were sorted by 'Barcode' so that solid tumor samples were immediately followed by the matched blood sample. The manifest files for matched BRCA and normal blood samples were downloaded and placed into a file labeled 'Blood' to be consistent with the language of the BreastBlood. sh coding program (Stoll 2016 SOM Figure 1A -BreastBlood) written specifically for the current study. The manifest files were subsequently processed with the BreastBlood.sh to create .csv output files (from the original .xml manifest files). The original programming code, BreastBlood.sh, and output files (Stoll 2016 SOM Figure 1E -BreastBlood Variants) are provided in the SOM. Note that the output files have been further processed using various macros, also provided in the SOM, to eliminate previously identified variants that will not be included in analysis. BreastBlood.sh was designed to identify variants in cytoskeletal protein-related coding regions (CPCRs). The CPCR list was generated from the study by Parry and Blanck (5), representing the most commonly mutated CPCRs in five cancer datasets that were investigated plus two additional CPCRs that are commonly mutated in the melanoma (skin cutaneous melanoma) dataset, which were not evaluated in the previous study (5) . The CPCRs are presented in Table I .
Use of SNP databases and the PROVEAN web tool. Two SNP databases [All SNPs(142) and 1000 Genomes; genome.ucsc. edu] were used to filter the previously identified variants in the raw sequence files representing the matched BRCA and Table II . In addition, the SIFT analysis P<0.05 was considered to indicate a statistically significant difference.
Results

SNVs unique to individuals of the BRCA study set and representing deleterious amino acids.
To assess SNVs potentially present in CPCRs (Table I) of BRCA and normal blood samples of a single individual, a series of processing steps, indicated in Fig. 1 were performed. Any SNVs that were present in the All SNPs(142) and 1000 Genome SNP databases ( Fig. 1) were eliminated from further consideration. In addition, any SNVs that were not verified by 20 reads or more were eliminated from consideration. Results indicated that 29 barcodes had CPCR SNVs, i.e., nucleotides not matching the reference human genome (Fig. 2 ). Of these, 14 barcodes represented deleterious amino acid replacements, according to PROVEAN analysis, in the following coding regions: TTN, MUC4, FLG, DST, DNAH7, FAT3, DNAH10, RELN, MUC16, ANK2, SYNE2 and NEB (Table II) . The SIFT analysis indicated 21 damaging mutations (SOM Excel file labeled, 'Stoll 2016 SOM Figure 1F -Provean Results, aa variants unique to a barcode').
SNVs shared among members of the BRCA study set, but not present in common SNP databases. The results of the current SNV analyses indicated that a number cancer-/blood-matched CPCR SNVs were shared between barcodes in this analysis group of 31 barcodes, despite using the above two SNP databases to clear the known SNPs. Fig. 3 demonstrates the chromosome and nucleotide positions of the cancer-/blood-matched SNVs identified in more than one barcode, as well as the number of barcodes with a given variant. These SNVs were also analyzed using the PROVEAN tool (Table III ; Stoll 2016 SOM Figure 1G -Provean Results, aa variants present in more than one barcode). A summary of the specific, non-unique CPCR SNVs is provided in Table III . Thus, 112 SNVs unique to one individual ( Fig. 2 ) indicated 16 deleterious AA substitutions (Table II) , whereas 29 SNVs shared among the barcodes represented zero deleterious AA substitutions, using the PROVEAN analysis (P<0.00002; Student's t-test). The SIFT analysis detected 21 deleterious AA among the unique, matched SNVs, and there were three deleterious AA substitutions among the shared, matched SNVs. The SIFT analysis maintains the trend indicated by the PROVEAN analysis, but was not statistically significant.
Discussion
The above data and analyses indicate that systemic mutations in CPCRs are relatively common, consistent with the large size of these coding regions. In general, systemic, de novo mutations are considered sporadic and unpredictable, as in the case of Rett's syndrome, which can be caused by a point mutation in methyl CpG binding protein-2 (6). However, the large size of the CPCRs renders it more likely that de novo, or relatively recently generated SNVs, will be present in the CPCRs. Furthermore, the above analyses indicate that SNVs that lead to deleterious amino acid substitutions are more common when not shared. The relatively common occurrences of these de novo, systemic deleterious amino acid substitutions in CPCRs raises questions regarding the value of evaluating these coding regions. For example, small coding regions are unlikely to have de novo mutations and, thus, there may not be a practical justification for routine analysis. However, if de novo CPCR SNVs are identified to be essentially inevitable, investigating them would be valuable, particularly with regard to potentially identifying deleterious amino acid alternations. Such routine analysis may have value in better understanding a range of medical conditions, for example heart disease, due to the major role of various CPCRs in the formation of the sarcomere cytoskeleton (7). In addition, the results cause us to query other coding region groups, where individual group members may be too small to regularly reveal systemic mutations. The entire group collection, however, may be large enough such that de novo systemic mutations would alter one member of the group often enough to justify screening. For example, a comprehensive collection of tumor suppressor genes would likely have a member that represents a systemic mutation, due to random chance, fairly often. While such a collection is not likely to be as large as a CPCR collection, it is likely a large enough portion of genome, with mutations affecting a large enough number of individuals, to justify screening. Furthermore, due to the degeneracy of numerous tumor suppressor signaling pathways (8), a mutation in any one tumor suppressor, among a set, may represent pre-disposition to cancer.
In conclusion, SNPs not present in the SNP databases used here, but that were present in more than one of the individuals investigated above, and potentially present in other SNP databases, were detected. However, as all of the individuals analyzed in the current study were BRCA patients, the outcome of multiple shared SNVs results in the hypothesis that certain de novo, systemic CPCR mutations may facilitate BRCA development. Future studies are required to address the occurrence of potential, cancer specific SNVs in the CPCR set by repeating the above analyses for multiple types of cancer.
